WHO Issues Concern Over Acute Scarcity of Obesity Jabs
Less than one in 10 patients that would benefit from GLP-1 drugs like Wegovy can access them, warns the World Health Organization as it publishes its first advice on the therapies.
With in excess of 1,000,000,000 people worldwide now living with obesity, it is urging more widespread and fairer availability to this class of drugs.
Per estimates, more than two billion will be obese by 2030 if no action is taken.
"The new guidelines recognises that obesity is a lifelong illness that can be addressed with comprehensive and continuous treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are key obstacles to universal availability to the jabs that can help people shift substantial weight, notes the agency.
Skinny Jab Supply Crisis
Despite the present best projected case, the production of such drugs would only suffice for approximately 100 million people – under 10% of those who need them, according to the WHO.
The guideline calls on nations and manufacturers to expand access, via measures like patent sharing.
The intellectual property rights on the active ingredient – the core component of Novo Nordisk's Wegovy – is due to expire in a number of nations in 2026.
The Way Weight-Loss Drugs Work
These medications mimick a biological compound to slow digestion, suppress the appetite and enhance satiety so individuals eat less.
Patients typically begin shedding pounds after several weeks of starting on the regular doses.
Research indicates patients may see weight return after a year of discontinuing the medication, as their normal hunger return.
To be carrying excess weight elevates your likelihood for experiencing health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity impacts individuals in all nations and was linked to millions of fatalities worldwide in 2024, per the health agency.
